Results 191 to 200 of about 982,573 (275)

Key takeaways from the updated multidisciplinary European MASLD guidelines. [PDF]

eGastroenterology
Horn P, Tacke F.
europepmc   +1 more source

Roles of myokines in osteoporosis under physiological and diabetic conditions. [PDF]

Front Endocrinol (Lausanne)
Ji X, Hu X, Xu T, Yang W.
europepmc   +1 more source

Molecular signatures of skeletal muscle insulin resistance: bringing personalised diabetes treatment a step closer. [PDF]

Signal Transduct Target Ther
Levate G, Stimson RH.
europepmc   +1 more source

Gαs defines the fundamental coupling mechanism of insulin secretion. [PDF]

J Diabetes Investig
Shirakawa J.
europepmc   +1 more source

GLP-1 Receptor Agonists - Good for Body Weight, Bad for Micronutrient Status? [PDF]

Curr Dev Nutr
Kerlikowsky F, Krämer K, Eggersdorfer M, Hahn A.   +3 more
europepmc   +1 more source

Prevention of cardiovascular disease in women with type 2 diabetes: the role of incretin mimetics and sodium-glucose cotransporter-2 inhibitors. [PDF]

Am J Physiol Cell Physiol
Ibrahim E, Burken M, Lastra G, Manrique-Acevedo C.   +3 more
europepmc   +1 more source

Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors. [PDF]

EBioMedicine
Khalil A, Velikyan I, Xiong M, Bossart M, Wagner M, Eriksson O.   +5 more
europepmc   +1 more source

Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review. [PDF]

World J Cardiol
Brar AS, Khanna T, Sohal A, Hatwal J, Sharma V, Singh C, Batta A, Chandra P, Mohan B.   +8 more
europepmc   +1 more source

Novel Therapeutic Strategies for Obesity-Related Glomerulopathy. [PDF]

Curr Hypertens Rep
Liu Y, Eirin A, Lerman LO.
europepmc   +1 more source

A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. [PDF]

Diabetes
Samms RJ, Sloop KW.
europepmc   +1 more source